00:00 / 57:08
#1 Introduction
#1
Introduction
#2
Why US strategies don’t work in Europe
01:51
#3
How Xcube.bio reinvented market entry for biotech
07:23
#4
A new win-win model that shares risks and rewards
11:00
#5
100 biotech conversations: what ceos really struggle with
13:03
#6
How Xcube.bio helps late-stage biotech reach patients faster
15:38
#7
What European payers expect — and why value matters most
18:08
#8
US vs Europe: two very different market realities
21:44
#9
Who takes the risk when a launch fails
30:44
#10
Launching in Europe: It's not only a matter of money
33:44
#11
Why Chinese biotechs and global players look to Europe
39:17
#12
The future of biotech in Europe — threats and opportunities
45:33
#13
The projets of Xcube.bio for the next 5 years
51:38
#14
Pierre-Henri's advice for European policymakers
53:31
#44 - Why Europe is missing 100 new drugs: Pierre-Henri Belin’s call for change
“Europe is missing too many innovations.”
I had the pleasure of welcoming Pierre-Henri Belin, the Co-Founder and CEO of Xcube.Bio — an innovative company that accelerates biopharma market entry across Europe.
By combining capital, deep expertise, and industry knowledge, Xcube.Bio helps mitigate risks and launch transformative solutions.
Pierre-Henri is a leading voice in pharmaceutical innovation and healthcare transformation. In this episode, he shares a bold vision to bridge one of Europe’s most urgent healthcare gaps: the slow access to new drugs for European patients.
In this conversation, we discuss:
◾️ The alarming gap between the United States and Europe — with more than 100 new drugs available in the US but still not accessible to European patients.
◾️ Why this gap exists, from fragmented regulatory systems to national-level decision-making and the lack of early collaboration between key actors.
◾️ The consequences for patients, innovation, and the competitiveness of Europe’s healthcare ecosystem.
◾️ Pierre-Henri’s proposed model, built on transparency, collaboration, and shared responsibility — connecting innovators, regulators, and patients earlier in the process.
◾️ A message of hope, showing that Europe can reinvent its system without sacrificing safety or trust, but only if we act collectively and decisively.
A clear, concrete, and inspiring episode that sheds light on how Europe can regain its leadership in healthcare innovation.
Many thanks to Xcube.Bio for supporting this episode. Their partnership allows us to push our explorations further — but the spirit of Pharma Minds remains unchanged: full editorial independence and complete freedom in choosing our guests.
—
Find Pierre-Henri Belin:
LinkedIn: https://www.linkedin.com/in/phbelin/?originalSubdomain=ch
Xcube.Bio: https://xcube.bio/
Resources mentioned in the episode:
📌 Deloitte Partner: Hanno Ronte
📌 M&A Specialist: Jan Boehler
📌 Former CFO of Big Pharma: Ludo Ooms
📌 Bluebird Bio (now Genetix Biotherapeutics): https://share.google/KHHhGp5HPvr5sDNkE
📌 Agios
Pharma Minds episodes mentioned:
Frédéric Prince on the Bluebird adventure in France (in English):https://smartlink.ausha.co/pharma-minds/frederic-prince-early-development-program-lead-oncology-roche-do-more-was-not-attractive-anymore
—
🎧 New here? To get a quick overview of the episodes, download “25 Tips for Purposeful Leadership”, a guide inspired by the best advice shared by my guests.
🤝 Want to connect or talk about your current challenges? Let’s connect on LinkedIn.
📩 Curious to dive deeper into the major shifts in the healthcare ecosystem? Subscribe to the Pharma Minds newsletter.
Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.
Powered by Ausha 🚀